# MaveriX Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/maverix-oncology

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.maverixoncology.com
- Total disclosed funding: $6.5M
- Latest round: Series A (Oct 14, 2019)
- Investors on record: 1

## About

MaveriX Oncology, Inc. is focused on developing innovative targeted therapeutics for solid tumors, utilizing advanced technology to enhance treatment effectiveness while reducing side effects.Founded in 2014 and headquartered in Palo Alto, US, MaveriX Oncology specializes in creating targeted therapies for oncology. The firm has engaged in one funding round, receiving a Series A investment led by PPF Group on October 14, 2019, totaling USD 6.5 mn. The company is led by CEO Steven Everett, who has a background in oncology ventures.MaveriX Oncology specializes in the development of novel targeted therapeutics aimed at treating solid tumors, utilizing Conditionally Activated Small Molecule Therapeutics. This approach focuses on co-targeting both cancerous cells and the tumor immune microenvironment, which is critical in enhancing treatment efficacy and minimizing side effects. The company's products address significant unmet medical needs in oncology, particularly for patients with advanced solid tumors, and are primarily intended for healthcare providers and institutions involved in cancer treatment in North America and Europe.MaveriX Oncology operates on a B2B model, engaging in partnerships with healthcare institutions and pharmaceutical companies to deliver its therapeutics. The revenue structure involves licensing agreements and collaborative research initiatives, wherein clients may subscribe to ongoing development programs or purchase therapeutic candidates as they progress through clinical trials. The framework may include milestone payments linked to specific clinical development goals and royalties on future sales of marketed products, with the company's flagship therapeutic offerings anticipated to be competitively priced within the advanced oncology market.MaveriX Oncology plans to leverage the recent Series A funding of USD 6.5 mn from PPF Group to advance its product pipeline and expand its market presence. The company is focused on launching new therapeutics designed to target solid tumors and aims to enter additional markets across Europe and North America by 2023. This strategic expansion is aimed at addressing the needs of underserved patient populations and enhancing its collaborative efforts with healthcare institutions.

## Funding rounds

- Series A, Oct 14, 2019, $6.5M — PPF Group

## Investors

- PPF Group (https://capitalatlas.ai/funds/ppf-group) — Series A